N,N-dimethylthiazole-2-carboxamide | 64649-21-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N,N-dimethylthiazole-2-carboxamide
• 英文别名: thiazole-2-carboxylic acid dimethylamide；2-N,N-dimethylcarbamoylthiazole；N,N-dimethyl-1,3-thiazole-2-carboxamide
• CAS: 64649-21-4
• 化学式: C₆H₈N₂OS
• 分子量: 156.208
• InChiKey: RUIYFLYPCWCVRD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  61.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N,N-dimethylthiazole-2-carboxamide 在 tetraphosphorus decasulfide 作用下， 以 苯 为溶剂， 生成 thiazole-2-carbothioic acid dimethylamide
  参考文献：
  名称：

  通过动态NMR-VI 1进行的构象研究：5元杂芳族氨基甲酰胺和硫代氨基甲酰胺中的扭转势垒

  摘要：

  已通过其NMR的总线形（TLS）分析测量了一系列5元杂芳族N，N-二甲基氨基甲酰胺和-硫代氨基甲酰胺中涉及部分CN双键旋转的热力学参数。在两种情况下已应用镧系元素诱导的位移（LIS）来确定CO部分相对于杂原子的构象。发现噻唑基尿素和硫代尿素的能垒比呋喃基和噻吩基类似物大，并通过微扰分子轨道分析进行了解释。

  DOI：

  10.1016/0040-4020(77)84082-9
• 作为产物：
  描述：

  噻唑-2-甲酸 、 二甲胺 生成 N,N-dimethylthiazole-2-carboxamide
  参考文献：
  名称：

  通过动态NMR-VI 1进行的构象研究：5元杂芳族氨基甲酰胺和硫代氨基甲酰胺中的扭转势垒

  摘要：

  已通过其NMR的总线形（TLS）分析测量了一系列5元杂芳族N，N-二甲基氨基甲酰胺和-硫代氨基甲酰胺中涉及部分CN双键旋转的热力学参数。在两种情况下已应用镧系元素诱导的位移（LIS）来确定CO部分相对于杂原子的构象。发现噻唑基尿素和硫代尿素的能垒比呋喃基和噻吩基类似物大，并通过微扰分子轨道分析进行了解释。

  DOI：

  10.1016/0040-4020(77)84082-9

文献信息

• PYRAZOLE DERIVATIVES
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP1762568A1

  公开（公告）日：2007-03-14

  A compound represented by formula (I): (wherein Ar1 represents a phenyl group which may have 1 to 3 substituents, or a non-substituted 5- or 6-membered aromatic heterocyclic group; Ar2 represents (i) a non-substituted phenyl group, (ii) a phenyl group which has been substituted by a lower alkyl group having 1 to 3 groups or atoms selected from among a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom, or (iii) a 5- or 6-membered nitrogen-containing aromatic heterocyclic group which has been substituted by 1 to 3 groups or atoms selected from among a lower alkyl group, a lower alkynyl group, a lower alkanoyl group, a carbamoyl group, a cyano group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom; and X represents a group represented by formula (II): (wherein the ring structure represents a 4- to 7-membered heterocyclic group which may have, in addition to the nitrogen atom shown in formula (II), one heteroatom selected from among nitrogen, oxygen, and sulfur, and which may be substituted by 1 to 4 groups or atoms selected from among a lower alkyl group, a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, an oxo group, a lower alkanoyl group, a lower alkylsulfonyl group, and a halogen atom)), a salt thereof, a solvate of the compound or the salt, and a drug.

  由式(I)表示的化合物： （其中Ar1代表可能具有1到3个取代基的苯基，或者是非取代的5-或6-成员芳香杂环基团；Ar2代表（i）非取代的苯基团，（ii）已被1到3个来自羰胺基、氨基、羟基、低烷氧基和卤原子的群或原子取代的较低烷基基团取代的苯基团，或者（iii）已被1到3个来自低烷基基团、低炔基基团、低烷酰基团、羰胺基、氰基、氨基、羟基、低烷氧基和卤原子的群或原子取代的5-或6-成员含氮芳香杂环基团；X代表由式(II)表示的基团： （其中环结构表示可能具有除了式(II)中显示的氮原子之外，从氮、氧和硫中选择的一个杂原子的4-到7-成员杂环基团，并且可能被1到4个来自低烷基基团、羰胺基、氨基、羟基、低烷氧基、氧基、低烷酰基团、低烷基磺酰基团和卤原子的群或原子取代）），其盐，该化合物或其盐的溶剂化合物，以及药物。
• 2-Thioethenyl substituted carbapenem derivatives
  申请人：Maruyama Takahisa

  公开号：US20070004700A1

  公开（公告）日：2007-01-04

  [Objective] An objective of the present invention is to provide compounds that are effective against various resistant bacteria which cause current clinical problems, for example, pneumococci including penicillin resistant Streptococcus pneumoneae (PRSP), Haemophilus influenzae including bata-lactamase-nonproducing ampicillin-resistant Haemophilus influenzae (BLNAR), and Moraxella ( Branhamella ) catarrhalis. [Structure] The present invention provides 2-ethenylthio-based carbapenem derivatives represented by the formula (I) or pharmaceutically acceptable salts thereof that are effective, for example, against pneumococci including penicillin resistant Streptococcus pneumoneae (PRSP), Haemophilus influenzae including beta-lactamase-nonproducing ampicillin-resistant Haemophilus influenzae (BLNAR), and Moraxella (Branhamella) catarrhalis:

  本发明的一个目标是提供对抗引起当前临床问题的各种耐药细菌有效的化合物，例如对抗青霉素耐药的肺炎球菌（PRSP）、包括产β-内酰胺酶非产生性氨苄青霉素耐药的流感嗜血杆菌（BLNAR）和喜马拉雅链球菌（布兰氏链球菌）等。本发明提供了以公式（I）表示的基于2-乙烯硫的碳青霉烯衍生物或其药用可接受盐，例如对抗青霉素耐药的肺炎球菌（PRSP）、包括产β-内酰胺酶非产生性氨苄青霉素耐药的流感嗜血杆菌（BLNAR）和喜马拉雅链球菌（布兰氏链球菌）有效。
• Cross Coupling of Acyl and Aminyl Radicals: Direct Synthesis of Amides Catalyzed by Bu4NI with TBHP as an Oxidant
  作者：Zhaojun Liu、Jie Zhang、Shulin Chen、Erbo Shi、Yuan Xu、Xiaobing Wan

  DOI：10.1002/anie.201108763

  日期：2012.3.26

  A radical solution: A Bu4NI/tert‐butyl hydroperoxide (TBHP) catalyzed synthesis of amides through a cross‐coupling reaction between acyl and aminyl radicals is described. This method involves the combination of aldehyde CH bond functionalization and decarbonylation of N,N‐disubstituted formamides (see scheme). The cross‐coupling is metal‐free, has a wide substrate scope, operational simplicity, and

  自由基溶液：描述了Bu 4 NI /叔丁基过氧化氢（TBHP）通过酰基和氨基自由基之间的交叉偶联反应催化的酰胺合成。该方法涉及醛CH键官能化和N，N-二取代甲酰胺的脱羰作用的组合（请参见方案）。交叉耦合是无金属的，具有广泛的基片范围，操作简便，并且按比例放大可提供高产量。
• [EN] TRICYCLIC PIPERIDINE COMPOUNDS<br/>[FR] COMPOSÉS PIPÉRIDINIQUES TRICYCLIQUES
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2015075023A1

  公开（公告）日：2015-05-28

  The present invention relates to compounds of the formula (I), wherein R, R1a, R1b, R2, R3, and X are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), to methods for the preparation of such compounds of formula (I), and especially to their use as TPH modulators.

  本发明涉及公式（I）的化合物，其中R、R1a、R1b、R2、R3和X如描述中所述，以及它们的制备方法，其药用盐，以及它们作为药物的用途，包括含有一个或多个公式（I）化合物的药物组合物，以及制备这种公式（I）化合物的方法，特别是它们作为TPH调节剂的用途。
• [EN] IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS<br/>[FR] DERIVES D'IMIDAZO-TRIAZINE COMME LIGANDS DE RECEPTEURS GABA
  申请人：MERCK SHARP & DOHME

  公开号：WO2002038568A1

  公开（公告）日：2002-05-16

  A class of 7-phenylimidazo [1,2-b][1,2,4]triazine derivatives, substituted at the meta position of the phenyl ring by an optionally substituted aryl or heteroaryl group which is directly attached or bridged by an oxygen atom or a -NH- linkage, being selective ligands for GABAA receptors, in particular having good affinity for the α2 and/or α3 and/or α5 subunit thereof, are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central nervous system, including anxiety, convulsions and cognitive disorders.

  一类7-苯基咪唑[1,2-b][1,2,4]三嗪衍生物，取代苯环的间位上，由一个可选择取代的芳基或杂环芳基基团直接连接或通过氧原子或-NH-键桥接，是选择性的GABAA受体配体，特别是对其α2和/或α3和/或α5亚单位具有良好的亲和力，因此对于治疗和/或预防中枢神经系统的不良症状，包括焦虑、惊厥和认知障碍是有益的。